This study investigated the effect of combined treatment with the FGF21 analog zalfermin and the glucagon-like peptide-1 receptor agonist semaglutide on body weight and plasma and liver biochemistry and histology in a mouse model of MASH. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.